by certify that this paper is	being facsimile transmitted to the Patent and Trademark Office on the date shown below.
	Type or print name of person signing certification

<u>PATENT APPLICATION</u> IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: Dally, et al. Group Art Unit: 1615

Serial No.: 10/521,896

Application Date: January 18, 2005 Conf No.: 8851

For: SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING

A PHENYLSULFONYL GROUP

Docket No.: X-15711

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of the listed document for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

/Gilbert T. Voy/

Attorney for Applicants Registration No. 43,972 Phone: 317-276-2966

Eli Lilly and Company Patent Division P.O. Box 6288 Indianapolis, Indiana 46206-6288 April 24, 2007